Go to content

Chronic lymphocytic-leukemia: associated incidence, prevalence, and treatment patterns in Ontario

Client: IQVIA Solutions Canada Inc.

Project ID: P2020-080 / 2022 0970 261 000

Research Question/Objectives: CLL is a type of blood cancer that begins in the bone marrow and usually develops slowly over months or years. In 2016, an estimated 1,745 Canadians were diagnosed with CLL. With the emergence of various therapies for CLL, it is important to understand the real world impact of CLL on the patient and the healthcare system. The analysis will examine characteristics of patients in the “watch and wait” status and patients that initiate 1st line (1L) treatment, by therapy type. This report will also help to validate/compare US-based CLL patient characteristics to a Canadian population.

Objectives:

  • Identify CLL patients within the administrative data held at ICES.
  • Describe the characteristics of these cancer patients in Ontario, including: incidence (i.e. new patients); prevalence (i.e. existing patients).
  • Describe the characteristics of these cancer patients in Ontario, stratified by 1L therapy type as sample size allows, including: demographic characteristics, clinical characteristics, and; treatment patterns of attending physician visits and medication use.

Results:

  • December 2022